We’ve provided over $100,000 in funding for the next phase of VEXAS research. The goal of this phase is to continue the search for additional genetic mutations in patients with autoimmune diseases and bring science closer to the discovery of a biomarker for RP. This project will leverage a collaborative network of talented researchers in the Inflammatory Disease Genetics Program at NYU Langone in the Center for Human Genetics and Genomics and Division of Rheumatology and the Relapsing Polychondritis and Autoinflammatory Clinics at the NIH.
The VEXAS research program is ongoing. We’ll be sure to update this section once it is complete. Learn more about VEXAS and the research we’re supporting here:
Result: Year’s best in discovery at the American Society of Hematology: https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V19.1.2022117/483395/This-Year-s-Best-in-Hematology-Diagnosis-A-New
Result: UBA1 mutations as a frequent driver of Relapsing Polychondritis: https://pubmed.ncbi.nlm.nih.gov/33779074/
Result: UBA1 mutations as a cause of Lupus: https://pubmed.ncbi.nlm.nih.gov/34463053/
Until recently, there were few options and even fewer resources for patients living with RP. We’re working every day to unlock the mysteries of RP and deliver hope to patients and their families.